Last reviewed · How we verify
Cergem (GEMEPROST)
Cergem (generic name: GEMEPROST) is a gemeprost drug. It is currently in Phase 2 development.
Gemeprost works by mimicking the action of prostaglandins, a group of hormone-like substances that play a role in various bodily functions.
Cergem, also known as Gemeprost, is a small molecule drug in the gemeprost class. It is used to treat certain conditions, but its exact target and approved indications are unknown. The commercial status of Cergem is unclear, and it is not known whether it is patented or available as a generic. Further research is needed to determine its key safety considerations and pharmacological properties. As a result, Cergem is not widely recognized in the pharmaceutical industry.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | GEMEPROST |
|---|---|
| Drug class | gemeprost |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
In simple terms, prostaglandins are like messengers that help different parts of the body communicate with each other. Gemeprost is a synthetic version of these messengers, which can help to relax muscles and improve blood flow. This can be beneficial in treating conditions where these processes are disrupted.
Approved indications
Common side effects
Key clinical trials
- Gemeprost Versus Dinoprostone in First Trimester Miscarriages (PHASE2)
- Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Termination of Pregnancy Analgesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cergem CI brief — competitive landscape report
- Cergem updates RSS · CI watch RSS
Frequently asked questions about Cergem
What is Cergem?
How does Cergem work?
What is the generic name of Cergem?
What drug class is Cergem in?
What development phase is Cergem in?
Related
- Drug class: All gemeprost drugs
- Therapeutic area: All drugs in Hematology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing